Dinaciclib SCH-727965 CAS: 779353-01-4

CAS NO: 779353-01-4
Dinaciclib SCH-727965
Chemical Name: (2S)-1-[3-Ethyl-7-[[(1-oxido-3-pyridinyl)methyl]amino]pyrazolo[1,5-a]pyrimidin-5-yl]-2-piperidineethanol
Molecular Formula: C21H28N6O2
Formula Weight: 396.49
CAS No.: 779353-01-4
Description Review
Description

Dinaciclib, also known as SCH-727965, is an experimental small-molecule drug that is currently being investigated as a potential treatment for various forms of cancer. This article will provide an overview of Dinaciclib, including its chemical properties, health benefits, potential effects, mechanism of action, safety, side effects, and dosing information.

Chemical Properties: Chemical name: (S)-1-(4-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(1-(2-hydroxyethyl)indol-3-yl)urea Molecular formula: C24H28N6O4 Formula weight: 464.52 g/mol CAS No: 779353-01-4

Top ten Google Keywords:

  1. Dinaciclib
  2. SCH-727965
  3. Cancer treatment
  4. Cell cycle regulator
  5. Quinazoline compound
  6. Clinical trials
  7. Cyclin-dependent kinase inhibitors
  8. Chemotherapy
  9. Targeted therapy
  10. Anticancer drug

Synonyms: DINACICLIB SCH 727965 SCH727965 SCH-727965A 779353-01-4 1-(4-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(1-(2-hydroxyethyl)indol-3-yl)urea

Health Benefits: Dinaciclib is a promising anticancer drug that has shown great potential in treating various types of cancer, including lung cancer, breast cancer, and hematologic malignancies. Dinaciclib works by inhibiting cyclin-dependent kinases (CDKs), which are crucial regulators of the cell cycle. By blocking CDKs, Dinaciclib stops tumors from growing, and actively induces tumor cell death.

Potential Effects: Dinaciclib has shown significant efficacy in preclinical trials, and several clinical trials are currently underway to investigate its efficacy in different cancers such as breast or lung cancers. In a Phase I clinical trial, Dinaciclib was well-tolerated and showed promising clinical activity in patients with relapsed/non-refractory leukemia.

Product Mechanism: Dinaciclib works by inhibiting various CDKs, which are key enzymes that regulate the cell cycle progression in various cell types. Dinaciclib targets the CDK1, CDK2, CDK5, and CDK9 enzymes and is known as a broad-spectrum CDK inhibitor. By exploiting the cell cycle checkpoint control mechanism, Dinaciclib triggers apoptosis or programmed cell death of cancer cells.

Safety: Dinaciclib has undergone extensive safety testing in preclinical trials and several phases of clinical trials to determine its safety and tolerability profile. However, Dinaciclib induces cytotoxicity and can cause some side effects like nausea, vomiting, fatigue, or myelosuppression.

Side Effects: Dinaciclib can cause some side effects, including:

  • Nausea and vomiting
  • Diarrhea
  • Fatigue
  • Headache
  • Dizziness
  • Myelosuppression
  • Encephalopathy
  • Cardiac toxicity

Dosing Information: The recommended dosage of Dinaciclib varies depending on the patient's condition, weight, and other factors. However, typical dosing regimens involve intravenous administration of Dinaciclib at 9-50 mg/m² every 3-4 weeks.

Conclusion: Dinaciclib is a promising anticancer drug that shows significant potential in treating various cancer types. Dinaciclib works by inhibiting crucial enzymes responsible for the cell cycle progression of cancer cells, inducing apoptosis, and ultimately killing the tumor cells. While further investigation is still needed in clinical trials, this drug has demonstrated to be a promising treatment option for cancer. Nevertheless, individual response and adverse reaction from this compound may differ depending on the patient's condition, and it is a physician's role to determine the appropriate dosage level and monitor their patient carefully during the administration of Dinaciclib.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code